Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinitapride SCHEMBL29453925 | 1.00 | MLNR (1.00) | MLNRADRB2CHRM1DRD2ADRA2B | |
| Cinitapride SCHEMBL29692032 | 0.95 | DRD2 (0.90) | MLNRADRB2CHRM1DRD2ADRA2B | |
| Cinitapride SCHEMBL1229865 | 0.95 | DRD2 (0.90) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL19235643 | 0.92 | MLNR (0.86) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL9867256 | 0.92 | MLNR (0.84) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL9865727 | 0.90 | MLNR (0.82) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL11946697 | 0.87 | MLNR (0.77) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL6903355 | 0.84 | MLNR (0.72) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL6903359 | 0.84 | MLNR (0.72) | MLNRADRB2CHRM1DRD2ADRA2B | |
| SCHEMBL13453078 | 0.83 | MLNR (0.71) | MLNRADRB2CHRM1DRD2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1076 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025037323-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DRY EYE DISEASE AND ASSOCIATED DISORDERS | KOTHAPUVARI PAVAN KUMAR (IN) | 2025-02-20 | — | — | WO | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| CN-119185590-A | Application of hydroxypropyl-beta-cyclodextrin in preparing solid preparation of valcidine, solid preparation and preparation method | 华润双鹤利民药业（济南）有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2005074931-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING (S) -PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004071374-A2 | ONCE A DAY ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-08-26 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1355698-A | Compound for medicine for treating function of bronchial contraction | RESPIRATORIUS AB (SE) | 2002-06-26 | — | — | CN | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| US-5026858-A | Used for treating nausea, vomating, gastrointestinal disorders and centarl nervous system | WALTON S.A. (ES) | 1991-06-25 | — | — | US | claimed |
| EP-0312423-A2 | Antiparasitic agents, processes for their production, and antiparasitic compositions, especially antimalerials containing these agents | INSTITUT PASTEUR (FR) | 1989-04-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | MLNR 37/4885ADRB2 279/4885CHRM1 1165/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | MLNR 1947/4885ADRB2 71/4885CHRM1 287/4885 |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | PMP22, VHL, PAX8 | MLNR 3551/4885ADRB2 1077/4885CHRM1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.